InMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022
September 19 2022 - 6:00PM
InMed Pharmaceuticals Inc. (“InMed” or the
“Company”) (Nasdaq: INM), a leader in the research, development and
manufacturing of rare cannabinoids, will report financial
results on Friday, September 23, 2022 for the fiscal year ended
June 30, 2022.
Conference Call & Webcast:Friday, September
23, 2022, at 10:00 AM Pacific Time, 01:00 PM Eastern
TimeRegistration Link:
https://register.vevent.com/register/BIa76ceda464264b3cae0b5ddb6e76a511Webcast
Link: https://edge.media-server.com/mmc/p/cnawzqhu(Webcast replay
available for 12 months)
To access the call by phone, please go to the registration link,
and you will be provided with dial in details. To avoid delays, we
encourage participants to register a day in advance or at a minimum
15 minutes before the start of the call.
The Company’s full financial statements and
related MD&A for the fiscal year ended June 30, 2022, will be
available at www.inmedpharma.com and at www.sedar.com.
About InMed: InMed
Pharmaceuticals is a global leader in the research, development and
manufacturing of rare cannabinoids, including clinical and
preclinical programs targeting the treatment of diseases with high
unmet medical needs. We also have significant know-how in
developing proprietary manufacturing approaches to produce
cannabinoids for various market sectors. For more information,
visit www.inmedpharma.com and www.baymedica.com.
Investor Contact: Colin ClancyVice President,
Investor Relations and Corporate CommunicationsT: +1.604.416.0999E:
cclancy@inmedpharma.com
Cautionary Note Regarding Forward-Looking
Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively,
"forward-looking information") within the meaning of applicable
securities laws. Forward-looking information is based on
management's current expectations and beliefs and is subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Forward-looking information in this news release
includes statements about: reporting financial results and business
updates for the fiscal year ended June 30, 2022, on September 23,
2022; being a leader in the research, development and manufacturing
rare cannabinoids; clinical and preclinical programs targeting
the treatment of diseases with high unmet medical needs; having
significant know-how in developing proprietary manufacturing
approaches to produce cannabinoids for various market sectors.
All forward-looking information herein is qualified in its
entirety by this cautionary statement, and InMed disclaims any
obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the
forward-looking information contained herein to reflect future
results, events or developments, except as required by law.
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Jun 2024 to Jul 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Jul 2023 to Jul 2024